Last reviewed · How we verify

hyaluronic acid-carboxymethylcellulose

Bucheon St. Mary's Hospital · FDA-approved active Small molecule Quality 5/100

hyaluronic acid-carboxymethylcellulose is a Small molecule drug developed by Bucheon St. Mary's Hospital. It is currently FDA-approved.

At a glance

Generic namehyaluronic acid-carboxymethylcellulose
SponsorBucheon St. Mary's Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about hyaluronic acid-carboxymethylcellulose

What is hyaluronic acid-carboxymethylcellulose?

hyaluronic acid-carboxymethylcellulose is a Small molecule drug developed by Bucheon St. Mary's Hospital.

Who makes hyaluronic acid-carboxymethylcellulose?

hyaluronic acid-carboxymethylcellulose is developed and marketed by Bucheon St. Mary's Hospital (see full Bucheon St. Mary's Hospital pipeline at /company/bucheon-st-mary-s-hospital).

What development phase is hyaluronic acid-carboxymethylcellulose in?

hyaluronic acid-carboxymethylcellulose is FDA-approved (marketed).

Related